共 132 条
[1]
Howard BV(2002)Prevention Conference VI: Diabetes and Cardiovascular disease: Writing Group I: epidemiology Circulation 105 e132-e137
[2]
Rodriguez BL(2002)Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study J Hypertens 20 1879-1886
[3]
Bennett PH(2004)Development of diabetes is retarded by ACE inhibition in hypertensive patients—a subanalysis of the Captopril Prevention Project (CAPPP) J Hypertens 22 645-652
[4]
Harris MI(1998)The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design Blood Press 7 176-183
[5]
Hamman R(2001)Characteristics of 15,314 hypertensive patients at high coronary risk. The VALUE trial. The Valsartan Antihypertensive Long-term Use Evaluation Blood Press 10 83-91
[6]
Kuller LH(2004)Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial Lancet 363 2022-2031
[7]
Lindholm LH(1985)Diabetes mellitus. Report of a WHO Study Group World Health Organ Tech Rep Ser 727 1-113
[8]
Ibsen H(1998)Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation Diabet Med 15 539-553
[9]
Borch-Johnsen K(2004)Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial Lancet 363 2049-2051
[10]
Olsen MH(2003)Lowering the criterion for impaired fasting glucose is in order Diabetes Care 26 3331-3332